Are we improving disease outcomes in IBD? A view from the epidemiology side

Gut

Volumn 63, Issue 10, 2014, Pages 1529-1530

  Gower Rousseau, Corinne ^a   Savoye, Guillaume ^b   Colombel, Jean Frédéric ^c   Peyrin Biroulet, Laurent ^d  

^a UNIV LILLE   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; MESALAZINE; TUMOR NECROSIS FACTOR INHIBITOR;

COHORT ANALYSIS; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE REGISTRY; DISEASE SURVEILLANCE; DRUG USE; ENDOSCOPY; EPIDEMIOLOGICAL MONITORING; FECES ANALYSIS; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; INTESTINE SURGERY; NOTE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; RISK REDUCTION; SAMPLE SIZE; SURGICAL RISK; TREATMENT DURATION; ULCERATIVE COLITIS; ABDOMINAL SURGERY; DRUG UTILIZATION; EPIDEMIOLOGY; FEMALE; IBD; MALE; STATISTICS; SURGERY FOR IBD;

EPIDEMIOLOGY; IBD; SURGERY FOR IBD;

COLITIS, ULCERATIVE; CROHN DISEASE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DRUG UTILIZATION; FEMALE; HUMANS; MALE;

EID: 84908551058     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-306045     Document Type: Note

References (18)

1. Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut 2014;63:1607-16.
2. Gisbert JP, Gomollón F, Hinojosa J, et al. Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain. J Crohns Colitis 2010;4:567-74.
3. Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumor necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011;60:930-6.
4. Frolkis AD, Dykeman J, Negron ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 2013;145:996-1006.
5. Bernstein CN, Loftus EV Jr, Ng SC, et al. Hospitalisations and surgery in Crohn's disease. Gut 2012;61:622-9.
6. Ramadas AV, Gunesh S, Thomas GA, et al. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010;59:1200-6.
7. Lakatos PL, Golovics PA, David G, et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol 2012;107:579-88.
8. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-63.
9. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. Am J Epidemiol 1989;129:678-702.
10. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1955-2005: a population-based study. Lancet 2007;369:750-6.
11. To T, Dell S, Dick PT, et al. Case verification of children with asthma in Ontario. Pediatr Allergy Immunol 2006;17:69-76.
12. Shah BR, Hux JE, Laupacis A, et al. Administrative data algorithms can describe ambulatory physician utilization. Health Serv Res 2007;42:1783-96.
13. Benchimol EI, Guttmann A, Griffiths AM, et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut 2009;58:1490-7.
14. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009;44:431-40.
15. Gower-Rousseau C, Vasseur F, Fumery M, et al. Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). Dig Liver Dis 2013;45:89-94.
16. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25.
17. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-8.
18. Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol 2013;29:397-404.